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Introduction
Worldwide, breast cancer is the most common cancer
among women after skin cancer, and is the second
leading cause of cancer death (after lung cancer) in
women. Available evidence suggests that breast cancer
might result from interactions between genetic elements
and a variety of possible environmental factors. Ethnicity
also plays a role in risk for breast cancer, with the
incidence varying from lowest in certain groups of Asian
women to highest in Caucasian women [1]. Asian-
Americans have traditionally had the lowest risk for breast
cancer in the USA, although the difference diminishes
over a couple of generations [1]. Comparison of
incidence–age curves for breast cancer in Asian and
Western genomic populations in their native countries
reveals an additional interesting difference. Age distributions
for East Asian groups exhibit an inverted ‘V’ shaped curve,
with the peak in the age range 40–50 years, contrasting
CI = confidence interval; ER = estrogen receptor; LN = lymph node; OR = odds ratio; PCR = polymerase chain reaction; SNP = single nucleotide
polymorphism; SSCP = single-strand conformation polymorphism; Tm, melting temperature.
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Abstract
Introduction: Receptor-mediated estrogen activation
participates in the development and progression of breast
cancer. Estrogen receptor (ER)-α polymorphism has been
found to be associated with breast cancer and clinical features
of the disease in Caucasians. Epidemiologic studies have
revealed that age–incidence patterns of breast cancer in
Asians differ from those in Caucasians. Genomic data for ER-α
in either population is therefore of value in the clinical setting
for that ethnic group.
Methods: A case–control study was conducted to establish a
database of ER-α polymorphisms in a Taiwanese population in
order to compare Western and Taiwanese (Asian) distributions
and to evaluate ER-α polymorphism as an indicator of clinical
outcome. The ER-α gene was scanned in a Taiwanese clinical
breast cancer group (189 patients) and in healthy individuals
(177 healthy control individuals). PCR single-strand
conformation polymorphism technology was employed and
real-time PCR melting curve analysis was performed.
Results: Three sites of silent single nucleotide polymorphism
(SNPs) were found, as reported previously in Western studies,
but at significantly different frequencies. Among the three
SNPs, the frequency of allele 1 (TCT → TCC) in codon 10 was
significantly lower in breast cancer patients (32.0%) than in
control individuals (40.4%; P = 0.018). We found that allele 1
(ACG → ACA) in codon 594 was less common in breast
cancer patients with a family history of breast cancer (5.9%)
than in  those without such a history (19.6%; P= 0.049).
Individually,  both allele 1 in codon 325 (CCC → CCG) and
allele 1 in codon 594 exhibited a reverse association with the
occurrence of lymph node metastasis. Furthermore,
incorporation of both SNP markers further increased predictive
accuracy.
Conclusions: Our data suggest that ER-α polymorphisms are
correlated with various aspects of breast cancer in Taiwan.
ER-α genotype, as determined during presurgical evaluation,
might represent a surrogate marker for predicting breast
cancer lymph node metastasis.
Keywords: estrogen receptor-α, lymph node, metastasis, polymorphism
Open AccessAvailable online http://breast-cancer-research.com/content/6/3/R180
R181
with the continued increasing incidence beyond age
50 years in Western women. The similar and apparently
unique manifestation of breast cancer in genetically similar
but geographically separated Asian groups suggests the
involvement of an unusual Asian genetic factor.
Breast cancer incidence has increased threefold in
Taiwan since 1980 (Annual Report of Cancer Incidence,
1970–1996, Department of Health, Taiwan) [2], leading
to the current focus on elucidating risk factors in this area.
Thus, in Taiwan special interest has focused on local
verses global breast cancer presentation and risk factors
because of the following factors: the Asian incidence peak
in middle age [3,4]; and the distinctive clinical features of
breast cancer patients at younger age in Taiwan, including
poor prognosis and weak association of standard
pathological factors (e.g. tumor grade, tumor and cell
morphology) with disease outcome [5].
It is known that breast cancer typically arises in luminal
epithelial cells of the mammary gland [6,7]. These cells
contain estrogen receptors (ERs), which respond to
ovarian estrogen in normal mammary gland development.
How estrogens stimulate cell growth is not fully under-
stood, but it is known that estrogen activation of ER
results in transcription of various genes that are involved in
cellular proliferation. It has been shown that exposure to
estrogen correlates with risk for breast cancer, with the
risk increasing with duration of exposure [8]. It has been
found that ERs are variably present in breast tumors, and
that patients expressing ERs are more responsive to
hormone treatment [9], making immunohistological assay
of ER expression in tumor tissue a widely applied clinical
technique. ER-α, which is expressed in luminal epithelium-
derived normal or cancerous cells but not in any of the
other stromal cell types within the human breast [10], has
been proposed to participate in breast carcinogenesis.
Mutation and polymorphism of cancer-associated genes
have been found to predict tumor formation and
prognosis. The human ER-α gene exhibits low mutational
frequency in breast cancer tissue [11]. However, ER-α
allelic variants have been associated with breast cancer
risk [12–14] in Caucasians, as have certain clinical
features including presence of a family history [11] and
lymph node (LN) metastasis [14], although no such
association was noted in one study [15]. At present the
literature contains little information regarding ER-α gene
expression, mutational frequency, and allelic variants in
breast cancer among Asians, especially those who reside
in their native country. Thus, the present study examined
ER-α polymorphism in a Taiwanese clinical group of
breast cancer patients in order to establish a genetic
polymorphism database for the ER-α encoding region of
the Taiwanese Asian genome, to compare this distribution
with that reported for Western study groups, and to test
for any correlation between ER-α polymorphism and
various clinically observable features of breast cancer in
Taiwanese women.
Methods
Study population
In the present case–control study, data for female breast
cancer patients and control individuals over the period
from 2000 to 2002 were evaluated. The breast cancer
patients (n = 189; median age 46.0 ± 10.7 years, range
34–85 years) were diagnosed at the Department of
General Surgery, National Cheng Kung University Hospital
and Tainan Hospital, Tainan, Taiwan. The diagnosis was
confirmed by histologic examination of mammectomy
specimens. The control group (n = 177; median age
43.0 ± 8.8 years, range 19–69 years) included healthy
women with no history of any type of cancer or any
relatives with a history of breast cancer. An ongoing
protocol to collect and store blood samples for future
genomic tests had been approved by the institutional
review board, and all patients provided written informed
consent to participate in that protocol before entering into
the present study.
Peripheral whole blood was collected and kept in storage
at –70°C until genotyping analysis. Individuals with at
least one first-degree or second-degree female relative
affected by breast cancer were considered to have a
family history. This information was obtained by interview
with patients and family members. The clinical
characteristics of the 189 breast cancer patients are
shown in Table 1.
Screening for estrogen receptor-α α variants by single
strand conformation polymorphism analysis
In order to identify any mutation or variant sites in the
Taiwanese population, our strategy was to screen initial
samples for the entire coding region of ER-α using the
PCR single-strand conformation polymorphism (SSCP)
method. A total of 30 breast cancer patients were
screened at this stage and compared with control
individuals in order to identify disease-associated variants/
mutations. Genomic DNA was extracted from purified
white blood cells using a Puregene DNA Isolation Kit
(Gentra Systems, Minneapolis, MN, USA) in accordance
with the manufacturer’s instructions. Genomic DNA
(50 ng) was used for each run of PCR-based genotyping.
Exons 1–8 of the ER-α gene were amplified by PCR
methods, using 10 sets of primers according to the
oligonucleotide sequences in 11. Optimal electrophoretic
separation for SSCP was conducted in 10% polyacryla-
mide gel in buffer (90 mmol/l Tris-borate and 2 mmol/l
EDTA) at 256 V for 2.6 hours at 4°C. After electro-
phoresis, the bands on gel were visualized using 3% silver
nitrate stain. PCR samples exhibiting varying band shifting
patterns were further purified using a High Pure PCRBreast Cancer Research    Vol 6 No 3 Hsiao et al.
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Product Purification kit (Boehringer–Mannheim, Mannheim,
Germany) and directly sequenced using a cycle
sequencing protocol to determine precise variant sites.
Genotyping by LightCycler® real-time PCR assay
Based on the initial screening results, three sets of
primers and probes were subsequently designed to
determine frequency variation by real-time PCR combined
with melting curve analysis using the LightCycler® system
(Roche Diagnostics, Basel, Switzerland). PCR was
performed using 2 µl LightCycler® FastStart Enzyme
mixture (LightCycler®-DNA Master Hybridization Probes
Kit) with 3 mmol/l MgCl2 and 0.5 µmol/l each of sense and
antisense primers. For genotype detection, 3 pmol of each
hybridization probe was added to the reaction mixture.
Each hybridization probe pair consisted of two
oligonucleotides: the sensor probe, labelled at the 3′ end
with LightCycler® LC Red 640 as an acceptor
flourophore; and the anchor probe, labelled at the 5′ end
with fluorescein as a donor. The amplitude of the emitted
fluorescence of the acceptor fluorophore from the LC Red
640 probes was recorded. The position and sequences of
the primers and hybridization probes are listed in Table 2.
PCR was performed for 40 cycles of 5 seconds at 95°C,
15 seconds at 55°C and 15 seconds at 72°C. After the
final cycle, melting temperature (Tm) analysis of all samples
and controls was performed over the range 37–77°C.
Genotypes were determined by amplicon Tm (Table 2).
Statistical analysis
χ2 testing was employed to assess the influence of
polymorphism status on features of breast cancer. Odds
ratios (ORs) with 95% confidence intervals (CIs) were
calculated using unconditional logistic regression.
Statistical analysis was performed using SPSS software
(version 9.0 for Windows; SPSS Inc., Cary, NC, USA).
Results
The encoding region of the ER-α gene of an initial 30
randomly selected breast cancer patients was screened
for mutation or variant sites by PCR-SSCP and DNA
sequencing. This stage of testing revealed no novel
mutations but it did reveal the presence, in the Taiwanese
population studied, of three silent single nucleotide
polymorphisms (SNPs) that have previously been
reported in Western study groups. Specifically, these
SNPs are as follows: codon 10 (TCT → TCC), codon 325
(CCC → CCG) and codon 594 (ACG → ACA). Then,
with primers constructed using data from this initial
screening (thus recognizing only these three SNPs), the
remainder of the patient and control groups were analyzed
with respect to the distribution of these three SNPs by
real-time PCR coupled with melting curve analysis. Tm
values were used to indicate specific allele types. In total,
189 patients with breast cancer and 177 healthy control
individuals were examined. The observed numbers of
individuals with different genotypes showed that all three
SNPs fitted the Hardy–Weinberg equilibrium for both
control and patient groups (P > 0.05).
Table 3 presents the genotypic and allelic frequencies
within the Taiwanese group studied, indicating the following:
the frequency of allele 1 in codon 10 is significantly less in
cancer patients (32.0%) than in control individuals
(40.4%;  P = 0.018); the frequency of allele 1 in codon
325 is lower in cancer patients (52.1%) than in control
individuals (58.2%), although the difference was not
statistically significant (P = 0.099); and the frequency of
allele 1 in codon 594 is lower in cancer patients with a
family history (5.9%) than in those without a family history
(19.6%) – a difference of 14% (P = 0.049).
ER-α genotypes were compared with selected clinical
breast cancer features, including age at onset, tumor size,
and LN metastasis. The only significant correlation was
found for LN metastasis, as indicated by the ORs
presented in Table 4. Genotype frequencies exhibited
different distributions in the presence and absence of LN
metastasis, with statistical significance for codon 325
(P = 0.013); statistical significance was almost achieved
for codon 594 (P = 0.062). The estimated risk was
threefold lower for individuals who were 11 homozygotic
in codon 325 (OR 0.3, 95% CI 0.11–0.82) or twofold
lower for those who were 01 heterozygotic in codon 594
(OR 0.5, 95% CI 0.22–0.98) than for the corresponding
Table 1
Clinical characteristics of the 189 breast cancer patients in the
study
Characteristic Proportion
Tumor type
Infiltrating ductal carcinoma 86.7%
Others 13.3%
Age of onset (years)
<40 20.1%
≥40 79.9%
Familial history
Negative 90.6%
Positive 9.4%
Tumour size
<5 cm 87.5%
≥5 cm 12.5%
LN metastasis
Absent 59.0%
Present 41.0%
ER expression in breast cancer tissue
Negative 31.7%
Positive 68.3%
ER, estrogen receptor; LN, lymph node.00 homozygote. Taking the two polymorphic sites
together, we noted that the greater the frequency of allele
1, the lesser the likelihood of LN metastasis. Patients in
the category with genotypes 01:11/11:01/11:11
exhibited the lowest OR of 0.19 (95% CI 0.05–0.71).
Because of the limited number for genotype 11:11
(n = 3), this subgroup was combined with patients
carrying 01:11/11:01. Our results demonstrated that a
combination of the two SNP markers may increase
accuracy in predicting LN metastasis.
Finally, we compared the known global geographical
distributions of ER-α polymorphism in codons 10, 325
and 594. Inspection reveals that only exons 1 and 4 are
significantly different in comparison with reported Western
genomic studies. Comparison of the data indicates the
following. The frequency of allele 1 in codon 10 is lower in
Taiwan (32.0%) than in the USA (44.9%), England
(41.0%) and Australia (51.0%). The frequency of allele 1
in codon 325 in Taiwan (52.1%) matches that in Korea
(50.0%), and is much more common than is found in USA,
England, Australia and Portugal (approximately 20%).
Finally, the frequencies of codon 594 in Taiwan, USA and
Australia are approximately equal (allele 1: 18.5%, 19.0%
and 24.0%, respectively). Thus, the Taiwanese population
exhibited a distinct pattern of ER-α polymorphism.
Discussion
Substantial evidence has been reported that indicates that
ER participates in mammary gland tumorigenesis, and
thus ER is among the genes that affect breast cancer
susceptibility. Breast cancer associated ER-α poly-
morphisms were surveyed in previous studies [11–16].
Somatic mutation of the ER-α gene has been identified
[17], but ER-α germ-line mutation rarely occurs in breast
cancer patients. In agreement with observed low mutation
rates, the present study found no novel mutations.
Unexplained differences between Asian and Western
breast cancer symptomatology and demographics led us
to consider whether unknown genetic factors within the
Taiwanese genome are involved, prompting us to conduct
the present PCR analysis of ER-α polymorphism.
Initial ER-α screening was conducted in 30 consecutive
breast cancer patients unselected for age or family history.
PCR primers used in the initial screening were from a US
study conducted in Caucasians [11]. Although the initial
PCR-based genotyping was able to detect new mutations,
none was found. However, the initial screening revealed the
presence in the Taiwanese population of three SNPs – in
codons 10 (TCT → TCC), 325 (CCC → CCG) and 594
(ACG → AGA) – that were previously reported for USA,
UK, Australian and Portuguese populations. Initial screening
Available online http://breast-cancer-research.com/content/6/3/R180
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Table 2
PCR primers and hybridization probes used in estrogen receptor-α α genotyping by real-time PCR combined with melting curve
analysis
Melting 
Polymorphism site temperature (°C) Oligonucleotide sequences
Exon 1/codon 10
TCT 56 Primers for PCR reaction:
TCC 64 Sense: 5′-GGTTTCTGAGCCTTCTGCCCTG-3′ (301–322)
Antisense: 5′-AGGCCGGTCTGACCGTAGA-3′ (593–575)
Hybridization probes:
Sensor: 5′-ACACCAAAGCATCCGGGATGred-3′ (377–396)
Anchor: 5′-fluoresceinCCCTACTGCATCAGATCCAAGGGAACG-3′ (398–424)
Exon 4/codon 325
CCC 58.5 Primers for PCR reaction:
CCG 65.5 Sense: 5′-ACCTGTGTTTTCAGGGATACGA-3′ (336–357)
Antisense: 5′-GCTGCGCTTCGCATTCTTAC-3′ (705–686)
Hybridization probes:
Sensor: 5′-GCTGAGCCCCCGATACTCTAred-3′ (554–573)
Anchor: 5′-fluoresceinCCGAGTATGATCCTACCAGACCCTTCA-3′ (576–602)
Exon 8/codon 594
ACG 61 Primers for PCR reaction:
ACA 67 Sense: 5′-CTGTGTCTTCCCACCTACAG-3′ (337–356)
Antisense: 5′-GGGTAAAATGCAGCAGGGATT-3′ (641–621)
Hybridization probes:
Sensor: 5′-TCCCTGCCACAGTCTGAGAGCred-3′ (575–595)
Anchor: 5′-fluoresceinCCCTGGCTCCCACACGGTTCAG-3′ (597–618)Breast Cancer Research    Vol 6 No 3 Hsiao et al.
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Table 3
Genotypic and allelic frequencies of estrogen receptor-α α in the Taiwanese population: breast cancer group versus control group
and breast cancer cases in the presence versus the absence of a family history 
ER-α genotypes ER-α
00 01 11 0 1
Exon 1, codon 10 (TCT → TCC)a
Breast cancer χ2 = 4.949, P = 0.026 χ2 = 5.566, P = 0.018
Cases (n = 189 subjects/378 alleles) 91 (48.1)d 75 (39.7) 23 (12.2) 257 (68.0) 121 (32.0)
Controls (n = 177 subjects/354 alleles) 69 (39.0) 73 (41.2) 35 (19.8) 211 (59.6) 143 (40.4)
Family history in case group χ2 = 0.387, P = 0.534 χ2 = 0.421, P = 0.517
Presence (n = 17 subjects/34 alleles) 12 (70.6) 1 (5.9) 4 (23.5) 25 (73.5) 9 (26.5)
Absence (n = 163 subjects/326 alleles) 76 (46.6) 70 (43.0) 17 (10.4) 222 (68.1) 104 (31.9)
Exon 4, codon 325 (CCC → CCG)b
Breast cancer χ2 = 2.910, P = 0.088 χ2 = 2.723, P = 0.099
Cases (n = 189 subjects/378 alleles) 43 (22.7) 95 (50.3) 51 (27.0) 181 (47.9) 197 (52.1)
Controls (n = 177 subjects/354 alleles) 25 (14.1) 98 (55.4) 54 (30.5) 148 (41.8) 206 (58.2)
Family history in case group χ2 = 1.020, P = 0.312 χ2 = 1.055, P = 0.304
Presence (n = 17 subjects/34 alleles) 4 (23.5) 11 (64.7) 2 (11.8) 19 (55.9) 15 (44.1)
Absence (n = 163 subjects/326 alleles) 38 (23.3) 76 (46.6) 49 (30.1) 152 (46.6) 174 (53.4)
Exon 8, codon 594 (ACG → ACA)c
Breast cancer χ2 = 0.003, P = 0.957 χ2 = 0.003, P = 0.956
Cases (n = 189 subjects/378 alleles) 128 (67.7) 52 (27.5) 9 (4.8) 308 (81.5) 70 (18.5)
Controls (n = 177 subjects/354 alleles) 117 (66.1) 55 (31.1) 5 (2.8) 289 (81.6) 65 (18.4)
Family history in case group χ2 = 3.605, P = 0.058 χ2 = 3.877, P = 0.049
Presence (n = 17 subjects/34 alleles) 15 (88.2) 2 (11.8) 0 (0.0) 32 (94.1) 2 (5.9)
Absence (n = 163 subjects/326 alleles) 107 (65.6) 48 (29.5) 8 (4.9) 262 (80.4) 64 (19.6)
Data are expressed as n (%). aAllele 0, TCT; allele 1, TCC. bAllele 0, CCC; allele 1, CCG. cAllele 0, ACG; allele 1, ACA.
Table 4
Estimated risk for lymph node metastasis with estrogen receptor-α α genotypes
LN metastasis (n = 156)
Genotype Absent (n = 92) Present (n = 64) P OR (95% CI)
Single site
Codon 10a
00 44 (54%) 37 (46%) 1.0 (reference)
01 35 (63%) 21 (37%) 0.194 0.7 (0.36–1.43)
11 13 (68%) 6 (32%) 0.6 (0.19–1.59)
Codon 325b
00 16 (50%) 16 (50%) 1.0 (reference)
01 43 (53%) 38 (47%) 0.013 0.9 (0.39–2.00)
11 33 (77%) 10 (23%) 0.3 (0.11–0.82)
Codon 594c
00 56 (53%) 49 (47%) 1.0 (reference)
01 32 (71%) 13 (29%) 0.062 0.5 (0.22–0.98)
11 4 (67%) 2 (33%) 0.6 (0.10–3.26)
Dual sites
codon 325:codon 594
00:00 12 (43%) 16 (57%) 1.00 (reference)
01:00 or 00:01 29 (49%) 30 (51%)
0.001
0.78 (0.31–1.92)
01:01 or 11:00 or 00:11 35 (71%) 14 (29%) 0.30 (0.11–0.79)
01:11 or 11:01 or 11:11 16 (80%) 4 (20%) 0.19 (0.05–0.71)
aGenotype 00, TCT/TCT; genotype 01, TCT/TCC; genotype 11, TCC/TCC. bGenotype 00, CCC/CCC; genotype 01, CCC/CCG; genotype 11,
CCG/CCG. cGenotype 00, ACG/ACG; genotype 01, ACG/ACA; genotype 11, ACA/ACA. LN, lymph node.Available online http://breast-cancer-research.com/content/6/3/R180
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was followed by more rapid real-time PCR and melting
curve analysis for the rest of the study population.
The frequencies of the three studied ER-α SNPs exhibited
a different pattern from that in Western study groups.
Comparison of the local Taiwanese ER-α genotype in
breast cancer patients with findings from other countries
indicates the following. Allele 1 in codon 10 is less
frequent in Taiwan than in the West. The frequencies of
allele 1 in codon 325 are similar between Asian areas,
including Taiwan and Korea, and greater than frequencies
in the West. Finally, frequencies of allele 1 in codon 594
are approximately equal for Taiwan, USA and Australia.
We conducted the comparison in order to clarify the
relation between demographics and ER-α polymorphism.
Demographically, the greatest variance between the Asian
and Western groups was found in codon 325. The
frequency of allele 1 in codon 325 was much greater in
the Asian population studied here than in Western
populations; this finding, together with the relatively low
incidence of breast cancer in Taiwan, suggests that this
SNP is protective against breast cancer.
In terms of practical utility, the relation between codon
325 and 594 variants and probability of LN metastasis
deserves further consideration as a clinical indicator
during presurgical evaluation, at least in the Taiwanese
population. Such a test is of interest because lymphatic
invasion is associated with local recurrence and disease
progression, and LN metastasis is considered an
important indicator when deciding whether chemotherapy
should be given [18–21]. Various studies of LN
metastasis have considered factors such as intrinsic
genetic factors involving cell mobility, vascular invasion
and angiogenesis. Large tumor size of the primary breast
cancer is known to increase the incidence of LN
metastasis [22]. In the present study, tumor size was
approximately equal by genotypes and alleles for all three
SNPs. However, data presented here show that there is a
negative correlation between allele 1 in codons 325 and
594 and LN metastasis, indicating that presence of allele
0 and absence of allele 1 may be independent parameters
for node positivity (Table 4). Our observation is in
agreement with a Portuguese study based on ER-α codon
325 PCR analysis of excised cancer tissue samples [16].
We further observed that allele 1 in codon 594 and allele
1 in codon 325 independently and additively decrease risk
for LN metastasis (Table 4). To our knowledge, the link
between silent polymorphisms and phenotypes is unclear.
One of the possibilities might be that the silent
polymorphism is in linkage with another genetic mutation
that directly affects breast cancer phenotype. The other
possibility might be that the nucleotide composition at the
silent polymorphic site could alter the gene expression
level of ER-α, thus leading to the association to LN
metastasis in breast cancer.
In conclusion, ER-α polymorphisms in a Taiwanese clinical
breast cancer group (189 breast cancer patients and 177
control individuals) were established using PCR SSCP
and real-time PCR technology with LightCycler® melting
curve analysis of peripheral blood. The same three SNPs
reported in Western studies were found in the Taiwanese
population studied, but at different frequencies than in
Western studies. Small but statistically significant
correlations were found between allele distribution, and
individual and familial manifestation of breast cancer.
Because of the limited sample size in the present study,
our finding of a correlation between LN metastasis and
allele 1 of codons 325 and 594 will require further
confirmation. This is planned as part of our future work,
because SNP determination from peripheral blood
represents a highly feasible and noninvasive option for
preoperative evaluation.
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